211 related articles for article (PubMed ID: 15161667)
1. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.
Schmidmaier R; Baumann P; Simsek M; Dayyani F; Emmerich B; Meinhardt G
Blood; 2004 Sep; 104(6):1825-32. PubMed ID: 15161667
[TBL] [Abstract][Full Text] [Related]
2. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism.
Kobune M; Chiba H; Kato J; Kato K; Nakamura K; Kawano Y; Takada K; Takimoto R; Takayama T; Hamada H; Niitsu Y
Mol Cancer Ther; 2007 Jun; 6(6):1774-84. PubMed ID: 17575106
[TBL] [Abstract][Full Text] [Related]
3. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.
Park HJ; Kong D; Iruela-Arispe L; Begley U; Tang D; Galper JB
Circ Res; 2002 Jul; 91(2):143-50. PubMed ID: 12142347
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation.
Lee MH; Cho YS; Han YM
Stem Cells; 2007 Jul; 25(7):1654-63. PubMed ID: 17464088
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells.
Li X; Liu L; Tupper JC; Bannerman DD; Winn RK; Sebti SM; Hamilton AD; Harlan JM
J Biol Chem; 2002 May; 277(18):15309-16. PubMed ID: 11839765
[TBL] [Abstract][Full Text] [Related]
6. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
Danesh FR; Sadeghi MM; Amro N; Philips C; Zeng L; Lin S; Sahai A; Kanwar YS
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8301-5. PubMed ID: 12048257
[TBL] [Abstract][Full Text] [Related]
7. Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi.
Cazzola M; Calzetta L; Page CP; Rinaldi B; Capuano A; Matera MG
Am J Respir Cell Mol Biol; 2011 Oct; 45(4):704-10. PubMed ID: 21278325
[TBL] [Abstract][Full Text] [Related]
8. Statins inhibit blastocyst formation by preventing geranylgeranylation.
Alarcon VB; Marikawa Y
Mol Hum Reprod; 2016 May; 22(5):350-63. PubMed ID: 26908642
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation.
Maeda T; Horiuchi N
J Biochem; 2009 Jun; 145(6):771-81. PubMed ID: 19254925
[TBL] [Abstract][Full Text] [Related]
10. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins.
Degraeve F; Bolla M; Blaie S; Créminon C; Quéré I; Boquet P; Lévy-Toledano S; Bertoglio J; Habib A
J Biol Chem; 2001 Dec; 276(50):46849-55. PubMed ID: 11591701
[TBL] [Abstract][Full Text] [Related]
11. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation.
Blanco-Colio LM; Villa A; Ortego M; Hernández-Presa MA; Pascual A; Plaza JJ; Egido J
Atherosclerosis; 2002 Mar; 161(1):17-26. PubMed ID: 11882313
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts.
Madonna R; Di Napoli P; Massaro M; Grilli A; Felaco M; De Caterina A; Tang D; De Caterina R; Geng YJ
J Biol Chem; 2005 Apr; 280(14):13503-11. PubMed ID: 15705589
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels.
Turner NA; O'Regan DJ; Ball SG; Porter KE
FASEB J; 2005 May; 19(7):804-6. PubMed ID: 15728660
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes.
Ishibashi T; Nagata K; Ohkawara H; Sakamoto T; Yokoyama K; Shindo J; Sugimoto K; Sakurada S; Takuwa Y; Teramoto T; Maruyama Y
Biochim Biophys Acta; 2002 Jun; 1590(1-3):123-30. PubMed ID: 12063175
[TBL] [Abstract][Full Text] [Related]
16. Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin.
Takeda N; Kondo M; Ito S; Ito Y; Shimokata K; Kume H
Am J Respir Cell Mol Biol; 2006 Dec; 35(6):722-9. PubMed ID: 16858009
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and mevalonate-rho kinase pathways.
Nagaoka T; Hein TW; Yoshida A; Kuo L
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):825-32. PubMed ID: 17251484
[TBL] [Abstract][Full Text] [Related]
18. 3-Hydroxymethyl coenzyme A reductase inhibition attenuates spontaneous smooth muscle tone via RhoA/ROCK pathway regulated by RhoA prenylation.
Rattan S
Am J Physiol Gastrointest Liver Physiol; 2010 Jun; 298(6):G962-9. PubMed ID: 20378830
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antimyeloma effects of zoledronate and simvastatin.
Schmidmaier R; Simsek M; Baumann P; Emmerich B; Meinhardt G
Anticancer Drugs; 2006 Jul; 17(6):621-9. PubMed ID: 16917207
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia.
Bi X; Baudry M; Liu J; Yao Y; Fu L; Brucher F; Lynch G
J Biol Chem; 2004 Nov; 279(46):48238-45. PubMed ID: 15364922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
